Chief Medical Officer Eyal Attar resigns effective April 18, 2025

Vor Biopharma Inc.

Eyal C. Attar, M.D., resigned as Chief Medical Officer of Vor Biopharma, effective April 18, 2025.
Resignation is to pursue a new opportunity; no successor named yet.
Company expects to enter into a consulting agreement for transition services.
Dr. Attar's departure may impact ongoing clinical development activities.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Eyal C. Attar, M.D.

Chief Medical Officer

VOR · Vor Biopharma Inc.

Effective: 2025-04-18
Filed: April 3, 2025, 7:59 PM ET

On March 31, 2025, Eyal C. Attar, M.D., notified Vor Biopharma Inc. (the “Company”) of his decision to resign as Chief Medical Officer of the Company, effective as of April 18, 2025, in order to pursue a new opportunity.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Eyal C. Attar, M.D. resigned as Chief Medical Officer at Vor Biopharma Inc..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On March 31, 2025, Eyal C. Attar, M.D., notified Vor Biopharma Inc. (the “Company”) of his decision to resign as Chief Medical Officer of the Company, effective as of April 18, 2025, in order to pursue a new opportunity.

View on SEC.gov

Vor Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-072340

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.